Streamlined.financeStreamlined.finance
MarketsFind Stocks

Incyte Corporation

NASDAQ

Market Cap.

13.84B

Avg. Volume

1.82M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Incyte Corporation

Incyte Corporation News

Incyte Corporation Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock
Website screenshot
HealthcareBiotechnology
incyte.com

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Incyte Corporation Earnings & Revenue

Incyte Corporation Financials

Table Compare

Compare INCY metrics with:

   

Earnings & Growth

INCY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

INCY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

INCY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

INCY

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Incyte Corporation Income

Incyte Corporation Balance Sheet

Incyte Corporation Cash Flow

Incyte Corporation Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Incyte Corporation Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Historical Market Cap

Shares Outstanding

Incyte Corporation Executives

NameRole
Mr. Herve HoppenotChief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer
Ms. Christiana Stamoulis M.B.A.Executive Vice President & Chief Financial Officer
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America
NameRoleGenderDate of BirthPay
Mr. Herve HoppenotChief Executive Officer & ChairmanMale19602.9M
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development19632.03M
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer19671.32M
Ms. Christiana Stamoulis M.B.A.Executive Vice President & Chief Financial OfficerFemale19711.18M
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America19581.01M

Incyte Corporation Insider Trades

Date2 Oct
NameDenton Sheila A.
RoleEVP & General Counsel
TransactionDisposed
TypeF-InKind
Shares2136
Date1 Oct
NameHeeson Lee
RoleEVP, Head of Incyte Intl
TransactionAcquired
TypeA-Award
Shares26447
Date1 Oct
NameHeeson Lee
RoleOfficer
TransactionDisposed
Type
Shares0
Date30 Sep
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeA-Award
Shares496
Date30 Sep
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeA-Award
Shares496
DateNameRoleTransactionTypeShares
2 OctDenton Sheila A.EVP & General CounselDisposedF-InKind2136
1 OctHeeson LeeEVP, Head of Incyte IntlAcquiredA-Award26447
1 OctHeeson LeeOfficerDisposed0
30 SepBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredA-Award496
30 SepBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredA-Award496

Discover More

Streamlined Academy

Incyte Corporation

NASDAQ

Market Cap.

13.84B

Avg. Volume

1.82M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Incyte Corporation News

Incyte Corporation Quantitative Score

Overall Score

Business

Growth

Unlock

Business

Quality

Unlock

Stock

Value

Unlock

Price

Move

Price

Momentum

Unlock

Price

Stability

Unlock

Incyte Corporation Earnings & Revenue

Incyte Corporation Income

Incyte Corporation Balance Sheet

Incyte Corporation Cash Flow

Incyte Corporation Financials Over Time

Incyte Corporation Executives

NameRole
Mr. Herve HoppenotChief Executive Officer & Chairman
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer
Ms. Christiana Stamoulis M.B.A.Executive Vice President & Chief Financial Officer
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America
NameRoleGenderDate of BirthPay
Mr. Herve HoppenotChief Executive Officer & ChairmanMale19602.9M
Dr. Pablo J. Cagnoni M.D., Ph.D.President and Head of Research & Development19632.03M
Dr. Steven H. Stein M.D.Executive Vice President & Chief Medical Officer19671.32M
Ms. Christiana Stamoulis M.B.A.Executive Vice President & Chief Financial OfficerFemale19711.18M
Dr. Barry P. Flannelly M.B.A., Pharm.D.Executive Vice President & GM of North America19581.01M

Incyte Corporation Insider Trades

Date2 Oct
NameDenton Sheila A.
RoleEVP & General Counsel
TransactionDisposed
TypeF-InKind
Shares2136
Date1 Oct
NameHeeson Lee
RoleEVP, Head of Incyte Intl
TransactionAcquired
TypeA-Award
Shares26447
Date1 Oct
NameHeeson Lee
RoleOfficer
TransactionDisposed
Type
Shares0
Date30 Sep
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeA-Award
Shares496
Date30 Sep
NameBAKER BROS. ADVISORS LP
RoleDirector, 10 percent owner
TransactionAcquired
TypeA-Award
Shares496
DateNameRoleTransactionTypeShares
2 OctDenton Sheila A.EVP & General CounselDisposedF-InKind2136
1 OctHeeson LeeEVP, Head of Incyte IntlAcquiredA-Award26447
1 OctHeeson LeeOfficerDisposed0
30 SepBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredA-Award496
30 SepBAKER BROS. ADVISORS LPDirector, 10 percent ownerAcquiredA-Award496

Streamlined Academy

Website screenshot
HealthcareBiotechnology
incyte.com

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

AI Generated Qualitative Analysis

AI

Your time is precious, so save it. Use AI to get the most important information from the business.

Learn about Incyte Corporation

Incyte Corporation Financials

Table Compare

Compare INCY metrics with:

   

Earnings & Growth

INCY

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

INCY

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

INCY

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

INCY

None

Debt/Assets Ratio

--

--

Assets/Liabilities Ratio

--

--

 

Incyte Corporation Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsStrong Sell
Debt/Equity RatioNeutral
Price/Earnings RatioStrong Sell
Price/Book RatioSell

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More

A Practical Guide: How To Analyze Any Stock (With Examples)